Skip to content
MarketScale
‹ Back to IndustriesHealthcare

THE OUTLOOK FOR ENZYME SUPPLEMENTS IS STRONGER THAN EVER

According to the market research firm Credence Research, Inc., the digestive enzyme supplements market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.9% over the coming years, reaching about $1.6 billion by 2025.[1] This growth is being driven by conditions like lactose intolerance, as well as a growing awareness and concern over those…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

According to the market research firm Credence Research, Inc., the digestive enzyme supplements market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.9% over the coming years, reaching about $1.6 billion by 2025.[1] This growth is being driven by conditions like lactose intolerance, as well as a growing awareness and concern over those wanting to improve their digestive health by using probiotics and prebiotics. Let’s take a look at the outlook of the enzyme supplement market.

The World Regions Driving the Growth of Enzyme Supplements

In 2016, the North American region was the world leader in revenue share for enzyme supplements. This can be attributed to consumers with gastrointestinal issues, an increased emphasis on maintaining a healthy lifestyle, and the growing access to dietary supplements from manufacturers and suppliers. The most rapidly growing market segment, however, was the Asia-Pacific region, which is expected to grow by over 7.5 % by 2024.[2] This is due to factors such as a large aging population and a dietary preference for oily and spicy food.

Enzyme Supplements Aid Digestion for a Large Segment of the Population

The human body produces 22 different types of enzymes.[3] Digestive enzymes are beneficial in easing the stress on the stomach, gallbladder, liver, small intestine, and pancreas when processing starches, fats, and proteins. Unfortunately, from time to time, the body may have shortages of certain digestive enzymes due to a number of issues. One such factor is lactase deficiency, commonly known as lactose intolerance, a condition that affects approximately 70% of the world’s population.[4] Gluten sensitivity is becoming more prevalent as well. Finally, the natural aging process itself greatly reduces the body’s ability to produce digestive enzymes, lowering digestive activity by as much as 50%.[5]

Enzyme Supplements Offer a Number of Important Benefits

Even those without a shortage of digestive enzymes realize a number of important benefits in taking enzyme supplements. Many consumers may experience gastrointestinal discomfort due to consuming fast food, sugars, and artificial preservatives and sweeteners that can negatively affect the gut flora that comprise the microbiome. In addition, there is a rising demand for natural sports nutrition products among athletes, fitness enthusiasts, and even casual exercisers looking to improve their performance and overall sense of well-being. Finally, an aging world population is looking for ways to stay healthy and vibrant during their golden years.

Deerland Enzymes & Probiotics is Positioned to Address this Growing Need

There can be no doubt that the outlook for enzyme supplements will be very strong in the years ahead. At Deerland, we work closely with our customers at the early concept phase of product development to ensure we are helping them to deliver the benefits consumers desire and that meet their specific needs. Our product development team creates a wide range of specialized supplement formulas that include enzymes, probiotics and prebiotics.

To learn more, please visit http://www.deerlandenzymes.com/products/ today.

[1] https://www.credenceresearch.com/press/global-digestive-enzymes-supplements-market

[2] https://www.gminsights.com/industry-analysis/enzymes-market

[3] https://www.credenceresearch.com/report/digestive-enzymes-supplements-market

[4] https://www.credenceresearch.com/report/digestive-enzymes-supplements-market

[5] https://www.credenceresearch.com/report/digestive-enzymes-supplements-market

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512